Natural polymorphisms of HIV-1 subtype-C integrase coding region in a large group of ARV-naïve infected individuals

Infection

Volumn 41, Issue 6, 2013, Pages 1097-1102

  Dimonte, S ^a,b,c   Babakir Mina, M ^a,c   Aquaro, S ^d   Perno, C F ^a,e,f  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b BioMolecular Lab   (Italy)

^c SULAIMANI POLYTECHNIC UNIVERSITY   (Iraq)

^d UNIVERSITY OF CALABRIA   (Italy)

^e NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^f TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Drug resistance; HIV; Integrase inhibitors; Polymorphism; Prevalence; Subtype C

Indexed keywords

AMINO ACID; ELVITEGRAVIR; INTEGRASE; RALTEGRAVIR; VIRUS DNA;

ANTIVIRAL RESISTANCE; ARTICLE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MOLECULAR INTERACTION; NONHUMAN; VIRUS MUTATION;

AMINO ACID SEQUENCE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, PROTEIN;

EID: 84890435142     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-013-0464-5     Document Type: Article

References (34)

1. Schrijvers R, Debyser Z. Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF. Expert Opin Pharmacother. 2012;13:1969-83.
2. De Clercq E. A cutting-edge view on the current state of antiviral drug development. Med Res Rev. 2013;. doi: 10.1002/med.21281.
3. Mouscadet JF, Delelis O, Marcelin AG, Tchertanov L. Resistance to HIV-1 integrase inhibitors: a structural perspective. Drug Resist Updat. 2010;13:139-50.
4. Liao C, Marchand C, Burke TR Jr, Pommier Y, Nicklaus MC. Authentic HIV-1 integrase inhibitors. Future Med Chem. 2010;2:1107-22.
5. Hemelaar J, Gouws E, Ghys PD, Osmanov S; WHO-UNAIDS Network for HIV Isolation and Characterisation. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS. 2011;25:679-89.
6. Wainberg MA, Brenner BG. The Impact of HIV genetic polymorphisms and subtype differences on the occurrence of resistance to antiretroviral drugs. Mol Biol Int. 2012;2012:256982.
7. Ceccherini-Silberstein F, Malet I, Fabeni L, Dimonte S, Svicher V, D'Arrigo R, Artese A, Costa G, Bono S, Alcaro S, d'Arminio Monforte A, Katlama C, Calvez V, Antinori A, Marcelin AG, Perno CF. Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. J Antimicrob Chemother. 2010;65:2305-18.
8. Nouhin J, Donchai T, Hoang KT, Ken S, Kamkorn J, Tran T, Ayouba A, Peeters M, Chaix ML, Lien TX, Nerrienet E, Ngo-Giang-Huong N. Natural polymorphisms of HIV-1 CRF01-AE integrase coding region in ARV-naïve individuals in Cambodia, Thailand and Vietnam: an ANRS AC12 working group study. Infect Genet Evol. 2011;11:38-43.
9. V3 signatures in the regulation of co-receptor usage. Retrovirology. 2011;8:33.
10. Dimonte S, Babakir-Mina M, Aquaro S, Perno CF. Specific VpU codon changes were significantly associated with gp120 V3 tropic signatures in HIV-1 B-subtype. Virol Sin. 2012;27:360-8.
11. Svicher V, Alteri C, D'Arrigo R, Laganà A, Trignetti M, Lo Caputo S, Callegaro AP, Maggiolo F, Mazzotta F, Ferro A, Dimonte S, Aquaro S, di Perri G, Bonora S, Tommasi C, Trotta MP, Narciso P, Antinori A, Perno CF, Ceccherini-Silberstein F. Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev. Antimicrob Agents Chemother. 2009;53:2816-23.
12. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011;28:2731-9.
13. Scherrer AU, von Wyl V, Götte M, Klimkait T, Cellerai C, Yerly S, Böni J, Held L, Ledergerber B, Günthard HF; Swiss HIV Cohort Study. Polymorphic mutations associated with the emergence of the multinucleoside/tide resistance mutations 69 insertion and Q151M. J Acquir Immune Defic Syndr. 2012;59:105-12.
14. McKee CJ, Kessl JJ, Shkriabai N, Dar MJ, Engelman A, Kvaratskhelia M. Dynamic modulation of HIV-1 integrase structure and function by cellular lens epithelium-derived growth factor (LEDGF) protein. J Biol Chem. 2008;283:31802-12.
15. Michel F, Crucifix C, Granger F, Eiler S, Mouscadet JF, Korolev S, Agapkina J, Ziganshin R, Gottikh M, Nazabal A, Emiliani S, Benarous R, Moras D, Schultz P, Ruff M. Structural basis for HIV-1 DNA integration in the human genome, role of the LEDGF/P75 cofactor. EMBO J. 2009;28:980-91.
16. Lu R, Ghory HZ, Engelman A. Genetic analyses of conserved residues in the carboxyl-terminal domain of human immunodeficiency virus type 1 integrase. J Virol. 2005;79:10356-68.
17. Lu R, Limón A, Ghory HZ, Engelman A. Genetic analyses of DNA-binding mutants in the catalytic core domain of human immunodeficiency virus type 1 integrase. J Virol. 2005;79:2493-505.
18. Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther. 2007;12:563-70.
19. Phuphuakrat A, Pasomsub E, Kiertiburanakul S, Chantratita W, Sungkanuparph S. HIV type 1 integrase polymorphisms in treatment-naive and treatment-experienced HIV type 1-infected patients in Thailand where HIV type 1 subtype A/E predominates. AIDS Res Hum Retroviruses. 2012;28:937-43.
20. Cannon PM, Byles ED, Kingsman SM, Kingsman AJ. Conserved sequences in the carboxyl terminus of integrase that are essential for human immunodeficiency virus type 1 replication. J Virol. 1996;70:651-7.
21. Johnson VA, Calvez V, Günthard HF, Paredes R, Pillay D, Shafer R, Wensing AM, Richman DD. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2011;19:156-64.
22. Passaes CB, Guimarães ML, Fernandez SL, Lorete RdosS, Teixeira SL, Fernandez JC, Morgado MG. Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil. J Acquir Immune Defic Syndr. 2009;51:7-12.
23. Fish MQ, Hewer R, Wallis CL, Venter WD, Stevens WS, Papathanasopoulos MA. Natural polymorphisms of integrase among HIV type 1-infected South African patients. AIDS Res Hum Retroviruses. 2010;26:489-93.
24. Papathanasopoulos MA, Vardas E, Wallis C, Glashoff R, Buttó S, Poli G, Malnati M, Clerici M, Ensoli B. Characterization of HIV type 1 genetic diversity among South African participants enrolled in the AIDS Vaccine Integrated Project (AVIP) study. AIDS Res Hum Retroviruses. 2010;26:705-9.
25. Rousseau CM, Birditt BA, McKay AR, Stoddard JN, Lee TC, McLaughlin S, Moore SW, Shindo N, Learn GH, Korber BT, Brander C, Goulder PJ, Kiepiela P, Walker BD, Mullins JI. Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes. J Virol Methods. 2006;136:118-25.
26. Isarangkura-Na-Ayuthaya P, Kaewnoo W, Auwanit W, de Silva UC, Ikuta K, Sawanpanyalert P, Kameoka M. Appearance of drug resistance-associated mutations in human immunodeficiency virus type 1 CRF01-AE integrase derived from drug-naive Thai patients. AIDS Res Hum Retroviruses. 2010;26:1341-3.
27. Eshleman SH, Hudelson SE, Smith P, Hackett J, Holzmayer V, Swanson P, Devare SG, Marlowe N. Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay. AIDS Res Hum Retroviruses. 2009;25:343-5.
28. Vartanian JP, Meyerhans A, Asjö B, Wain-Hobson S. Selection, recombination, and G → A hypermutation of human immunodeficiency virus type 1 genomes. J Virol. 1991;65:1779-88.
29. Malet I, Calvez V, Marcelin AG. The future of integrase inhibitors of HIV-1. Curr Opin Virol. 2012;2:580-7.
30. Quashie PK, Mesplède T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol. 2012;86:2696-705.
31. Bar-Magen T, Sloan RD, Faltenbacher VH, Donahue DA, Kuhl BD, Oliveira M, Xu H, Wainberg MA. Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes. Retrovirology. 2009;6:103.
32. Bar-Magen T, Donahue DA, McDonough EI, Kuhl BD, Faltenbacher VH, Xu H, Michaud V, Sloan RD, Wainberg MA. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays. AIDS. 2010;24:2171-9.
33. Brenner BG, Lowe M, Moisi D, Hardy I, Gagnon S, Charest H, Baril JG, Wainberg MA, Roger M. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors. J Med Virol. 2011;83:751-9.
34. Rhee SY, Liu TF, Kiuchi M, Zioni R, Gifford RJ, Holmes SP, Shafer RW. Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology. 2008;5:74.